Dr. Ruberg's clinical and research expertise is in the field of cardiac imaging including echocardiography and cardiovascular magnetic resonance imaging (CMR). Dr. Ruberg applies imaging in research designed to facilitate improved diagnosis and management of the infiltrative cardiomyopathy cardiac amyloidosis.
Diversity, Equity, Inclusion and Accessibility
I am deeply committed to developing an equitable and supportive clinical and research environment at BU/BMC. Through my nearly 2 decades of experience and leadership at BU/BMC, I have been focused on increasing representation of women and under-represented minority groups in medicine (URiM) in the clinical workforce while working to ensure that such populations are appropriately represented in research programs. Under my leadership as Program Director of the clinical fellowship training program and now Associate Chief of Cardiovascular Medicine, the cardiovascular medicine fellowship has achieved an approximate 50% women trainee census, and presently exceeds national census means for trainees who identify as URiM in cardiovascular medicine. I also serve as the Section lead of the BUMG campus-wide Commitment to Operationalize Racial Equity (CORE) program (to define and meet racial equity goals) and served as a member of the Department of Medicine Faculty Development and Diversity Committee before transitioning to my current position on the BUMG Women’s Leadership Advisory Council. My current clinical research team reflects this commitment, composed nearly entirely of women and/or URiM trainees. My primary research focus, hereditary transthyretin cardiac amyloidosis (ATTR), is a heart disease that disproportionately affects patients identifying as Black. I have served as PI on two awards from NIH that specifically focus on ATTR cardiac amyloidosis (most notably the ongoing Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations, or SCAN-MP study). Finally, since 2016, I have also meaningfully contributed to development of a diverse scientific workforce at BU by facilitating the careers of early investigators through my role as Director of Pilot Grant Award Program at the BU Clinical and Translational Science Institute.
Boston University Chobanian & Avedisian School of Medicine
Whitaker Cardiovascular Institute
Boston University Chobanian & Avedisian School of Medicine
Clinical and Translational Science Institute
Pilot Translational & Clinical Studies Program
The Boston University Clinical and Transitional Science Institute
04/15/2020 - 03/31/2025 (Key Person)
PI: Megan H. Bair-Merritt, MD, MSCENIH/National Center for Advancing Translational Sciences3UL1TR001430-08S1
Molecular Imaging of Primary Amyloid Cardiomyopathy
04/01/2017 - 03/31/2020 (Subcontract PI)The Brigham and Women's Hospital, Inc. NIH NHLBI5R01HL130563-04
Gadolinium-Free Myocardial Scar and Fibrosis Imaging with Ca
07/01/2020 - 06/30/2024 (PI)Beth Israel Deaconess Medical Center National Heart, Lung
Scan-MP (Screening fro cardiac amyloidosis with nuclear imag
05/01/2019 - 02/29/2024 (PI)The Trustees of Colombia University in the City of New York dba Colombia University National Heart, Lung
Screening for ATTR Amyloidosis among patients undergoing lumbar spinal stenosis decompression…
02/11/2020 - 02/11/2023 (PI)Akcea Therapeutics, Inc
2020 RD L – Cardiac Amyloidosis Fellowship U.S
10/26/2020 - 10/25/2022 (PI)Pfizer, Inc
2021 Transthyretin Cardiac Amyloidosis Fellowship
10/14/2021 - 10/13/2022 (PI)Pfizer, Inc
Alnylam - MGH study agreement (2019A017487)
09/01/2020 - 08/31/2022 (PI)Massachusetts General Hospital Alnylam Pharmaceutic
SCAN-MP Supplement SCREENING FOR CARDIAC AMYLOIDOSIS WITH NUCLEAR IMAGING IN MINORITY POPULATIONS (SCAN-MP) STUDY
09/01/2020 - 08/31/2022 (PI)Trustees of Columbia University National Heart, Lung
Longitudinal strain in ATTR cardiac amyloidosis
09/25/2017 - 09/25/2021 (PI)Eidos Therapeutics
Cardiac Amyloidosis Fellowship
01/01/2019 - 07/01/2021 (PI)Pfizer, Inc
2019 US ASPIRE for TTR Amyloidosis
09/23/2019 - 06/03/2021 (PI)Tufts Medical Center Pfizer, Inc
Showing 10 of 17 results.
Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 121 results.
Madhani A, Sabogal N, Massillon D, Paul LD, Rodriguez C, Fine D, Helmke S, Winburn M, Kurian D, Raiszadeh F, Teruya S, Cohn E, Einstein AJ, Miller EJ, Connors LH, Maurer MS, Ruberg FL. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. J Am Heart Assoc. 2023 Aug; 12(15):e028973.View Related Profiles. PMID: 37486082
Chan N, Einstein AJ, Griffin JM, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson LL, Kinkhabwala MP, Leb JS, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith SE, Winburn M, Smiley D, Miller EJ, Ruberg FL, Maurer MS. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. J Nucl Cardiol. 2023 Jun 13.View Related Profiles. PMID: 37311914
Ruberg FL. Finally Getting to the Heart of the Matter: Imaging Multiorgan Treatment Response in AL Amyloidosis. JACC Cardiovasc Imaging. 2023 Aug; 16(8):1053-1055. PMID: 37269271
Ruberg FL, Blaner WS, Chiuzan C, Connors LH, Einstein AJ, Fine D, Helmke S, Kurian D, Pandey S, Raiszadeh F, Rodriguez C, Sabogal N, Teruya S, Winburn M, Chung WK, Cohn E, Miller EJ, Kelly JW, Maurer MS. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. J Am Heart Assoc. 2023 Apr 18; 12(8):e028534.View Related Profiles. PMID: 37066788; PMCID: PMC10227254; DOI: 10.1161/JAHA.122.028534;
Amyar A, Fahmy AS, Guo R, Nakata K, Sai E, Rodriguez J, Cirillo J, Pareek K, Kim J, Judd RM, Ruberg FL, Weinsaft JW, Nezafat R. Scanner-Independent MyoMapNet for Accelerated Cardiac MRI T1 Mapping Across Vendors and Field Strengths. J Magn Reson Imaging. 2023 Apr 13. PMID: 37052580
Edmiston JB, Cohn EG, Teruya SL, Sabogal N, Massillon D, Muralidhar V, Rodriguez C, Helmke S, Fine D, Winburn M, Chiuzan C, Hod EA, Raiszadeh F, Kurian D, Maurer MS, Ruberg FL. Clinical and social determinants of health features of SARS-CoV-2 infection among Black and Caribbean Hispanic patients with heart failure: The SCAN-MP Study. PLoS One. 2023; 18(3):e0283730. PMID: 36996149; PMCID: PMC10062570; DOI: 10.1371/journal.pone.0283730;
Pandey S, Teruya S, Rodriguez C, Deluca A, Kinkhabwala M, Johnson LL, Fine D, Sabogal N, Winburn M, Castillo M, Bhatia K, Malkovskaya R, Raiszadeh F, Kurian D, Miller EJ, Einstein AJ, Maurer MS, Ruberg FL. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study. J Nucl Cardiol. 2023 Aug; 30(4):1414-1419.View Related Profiles. PMID: 36823486
Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 Mar 21; 81(11):1076-1126.View Related Profiles. PMID: 36697326; DOI: 10.1016/j.jacc.2022.11.022;
Valente CJ, Chiuzan C, Alreshq R, Blot T, Fine D, Helmke S, Rodriguez C, Sabogal N, Teruya S, Winburn M, Kurian D, Raiszadeh F, Maurer MS, Ruberg FL. Physical Performance in Black and Hispanic Outpatients With Heart Failure: The SCAN-MP Study. CJC Open. 2023 Apr; 5(4):292-302. PMID: 37124967; PMCID: PMC10140745; DOI: 10.1016/j.cjco.2022.12.011;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
Available to Mentor as: (Review Mentor Role Definitions)
Dr. Ruberg is Associate Chief of Cardiovascular Medicine for Academic Affairs and Director, Pilot Grants Program, BU Clinical and Translational Science Program. He is Associate Professor of Medicine and Radiology at Boston University School of Medicine. Dr. Ruberg is also Associate Program Director of the Cardiovascular Medicine Fellowship Training Program. An active clinical cardiologist and clinical investigator, Dr. Ruberg’s commitment to interdisciplinary research and team science is exemplified by his various responsibilities at BUMC. He is the Director of the Advanced Cardiac Imaging Program at Boston Medical Center – a clinical service involving clinicians and trainees in the Departments of Radiology and Medicine. His clinical interest is in infiltrative cardiomyopathy and he is a participating clinician and researcher in the multi-disciplinary BU/BMC Amyloidosis Center and Sarcoidosis Center. He is an internationally recognized expert in cardiac amyloidosis. His clinical and research expertise is in the field of cardiac imaging with interest in refining quantitative techniques for application in the clinical care of infiltrative cardiomyopathies. His research has been funded by the American Heart Association (AHA), Amyloidosis Foundation, industry, and NIH. Research collaboration include investigators in Boston, elsewhere in the US, and world-wide. Dr. Ruberg has served as Associate Editor of Circulation: Cardiovascular Imaging since 2016. He is a fellow of the American College of Cardiology and the American Heart Association. Dr. Ruberg is an active mentor of Internal Medicine residents and Cardiovascular Medicine fellows, having been awarding the 2017 Research Mentor of the year award from the IM residency. He serves on the Executive Committee of the newly funded NIH/NHLBI R38 award (Vasan Ramchandran, MD, PI) research in residency/StARR designed to facilitate research experiences for MD-trained IM residents.
Co-Mentor or Peer Mentor
Research / Scholarly Mentor
Work / Life Integration Mentor